ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy in estrogen receptor–positive (ER+) metastatic breast cancer and have been studied as a potential therapeutic target, as well as a predictive and prognostic biomarker. Nonetheless, the role of ESR1m as a possible mechanism of primary endocrine resistance, as well as whether it also occurs in tumors that are resistant to ET administered in early-stage disease as (neo)adjuvant, has not been adequately studied. In this study, we evaluated the prevalence of ESR1m in tumor samples from patients with ER+ breast cancer resistant to neoadjuvant aromatase inhibitor therapy.
Methods: We followed a prospective cohort of patients with ER+ HER2– stages II and III breast cancer treated with neoadjuvant endocrine therapy (NET). Tumor samples from patients with a pattern of primary endocrine resistance [defined as a Preoperative Endocrine Prognostic Index (PEPI) score of ≥4] were identified and analyzed for the presence of ESR1m.
Results: One hundred twenty-seven patients were included in the cohort, of which 100 (79%) had completed NET and underwent surgery. Among these patients, the PEPI score ranged from 0 to 3 in 70% (70/100), whereas 30% (30/100) had a PEPI score of 4 or more. Twenty-three of these patients were included in the analysis. ESR1 mutations were not identified in any of the 23 patients with early-stage ER+ breast cancer resistant to NET.
Discussion: Growing evidence supports the notion that there are different mechanisms for primary and secondary endocrine resistance. Our study suggests that ESR1 mutations do not evolve rapidly and do not represent a common mechanism of primary endocrine resistance in the neoadjuvant setting. Therefore, ESR1m should be considered a mechanism of acquired endocrine resistance in the context of advanced disease. Further research should be conducted to identify factors associated with intrinsic resistance to ET.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1093/annonc/mdy192
- https://doi.org//10.1146/annurev-med-070909-182917
- https://doi.org//10.1038/nrc3920
- https://doi.org//10.1158/1078-0432.CCR-13-2332
- https://doi.org//10.1038/s41523-018-0093-3
- https://doi.org//10.1158/1078-0432.CCR-15-0943
- https://doi.org//10.1126/scitranslmed.aac7551
- https://doi.org//10.1155/2019/1947215
- https://doi.org//10.1038/nrclinonc.2015.117
- https://doi.org//10.1055/s-0036-1597579
- https://doi.org//10.1007/s11864-018-0538-9
- https://doi.org//10.1200/JCO.2016.69.4406
- https://doi.org//10.1093/jncimonographs/lgv023
- https://doi.org//10.1016/j.ctrv.2016.08.008
SHARE
Usage metrics
